Department of Pharmaceutical/Medicinal Chemistry, Institute of Pharmacy, Friedrich-Schiller-University Jena, Philosophenweg 14, 07743, Jena, Germany.
Evonik Operations GmbH, Kirschenallee 45, 64293, Darmstadt, Germany.
Adv Sci (Weinh). 2023 Feb;10(6):e2205604. doi: 10.1002/advs.202205604. Epub 2022 Dec 25.
Specialized pro-resolving mediators (SPM), primarily produced in innate immune cells, exert crucial bioactions for resolving inflammation. Among various lipoxygenases (LOX), 15-LOX-1 is key for SPM biosynthesis, but cellular activation principles of 15-LOX-1 are unexplored. It was shown that 3-O-acetyl-11-keto-β-boswellic acid (AKBA) shifts 5-LOX regiospecificity from 5- to 12-lipoxygenation products. Here, it is demonstrated that AKBA additionally activates cellular 15-LOX-1 via an allosteric site accomplishing robust SPM formation in innate immune cells, particularly in M2 macrophages. Compared to ionophore, AKBA-induced LOX activation is Ca - and phosphorylation-independent, with modest induction of 5-LOX products. AKBA docks into a groove between the catalytic and regulatory domains of 15-LOX-1 interacting with R98; replacement of R98 by alanine abolishes AKBA-induced 15-LOX product formation in HEK293 cells. In zymosan-induced murine peritonitis, AKBA strikingly elevates SPM levels and promotes inflammation resolution. Together, targeted allosteric modulation of LOX activities governs SPM formation and offers new concepts for inflammation resolution pharmacotherapy.
特异性促解决介质 (SPM) 主要由先天免疫细胞产生,对解决炎症具有至关重要的生物作用。在各种脂氧合酶 (LOX) 中,15-LOX-1 是 SPM 生物合成的关键,但细胞激活 15-LOX-1 的原理尚不清楚。已经表明,3-O-乙酰-11-酮-β-乳香酸 (AKBA) 将 5-LOX 的区域特异性从 5-脂氧化产物转变为 12-脂氧化产物。在这里,证明 AKBA 通过变构位点进一步激活细胞 15-LOX-1,从而在先天免疫细胞中形成强大的 SPM,特别是在 M2 巨噬细胞中。与离子载体相比,AKBA 诱导的 LOX 激活不依赖于 Ca2+ 和磷酸化,并且 5-LOX 产物的诱导适度。AKBA 与 R98 结合在 15-LOX-1 的催化和调节结构域之间的凹槽中;用丙氨酸取代 R98 会使 AKBA 诱导的 HEK293 细胞 15-LOX 产物形成完全丧失。在酵母聚糖诱导的小鼠腹膜炎中,AKBA 可显著提高 SPM 水平并促进炎症消退。总之,靶向 LOX 活性的变构调节控制 SPM 的形成,并为炎症消退的药物治疗提供了新概念。